These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 1347112)

  • 21. Ondansetron versus dolasetron: a comparison study in the prevention of postoperative nausea and vomiting in patients undergoing gynecological procedures.
    Browning BA; Fort CA; Kemp KD; Shimata MF; Strube MD
    AANA J; 2004 Apr; 72(2):129-32. PubMed ID: 15098526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
    Lordick F; Ehlken B; Ihbe-Heffinger A; Berger K; Krobot KJ; Pellissier J; Davies G; Deuson R
    Eur J Cancer; 2007 Jan; 43(2):299-307. PubMed ID: 17134890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of oral granisetron versus intravenous ondansetron for antiemetic prophylaxis in patients undergoing laparoscopic surgery: the effect on emetic symptoms and quality of recovery.
    White PF; Tang J; Hamza MA; Ogunnaike B; Lo M; Wender RH; Naruse R; Sloninsky A; Kariger R; Cunneen S; Khalili T
    Anesth Analg; 2006 May; 102(5):1387-93. PubMed ID: 16632815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective survey of knowledge and perceptions of ondansetron: what do health care workers know about this drug?
    Marra C; Nimmo CR; Jewesson P
    Can J Hosp Pharm; 1995 Dec; 48(6):336-42. PubMed ID: 10153865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compliance with guidelines results in appropriate ondansetron prescribing at Christchurch Hospital.
    Busch AF; Pearce MJ; Allen B; Begg EJ
    N Z Med J; 1996 Apr; 109(1020):142-4. PubMed ID: 8649670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical development of ondansetron tablets.
    Leak RE; Woodford JD
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S63-6. PubMed ID: 2533901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ondansetron to prevent chemotherapy-induced vomiting.
    Drug Ther Bull; 1992 Mar; 30(6):21-3. PubMed ID: 1534293
    [No Abstract]   [Full Text] [Related]  

  • 28. Using ondansetron with pediatric patients undergoing total body irradiation.
    Witherow P; Wilson K
    Oncol Nurs Forum; 1991; 18(8):1416-7. PubMed ID: 1837082
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacological and anti-emetic properties of ondansetron.
    Tyers MB; Bunce KT; Humphrey PP
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S15-9. PubMed ID: 2533894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ondansetron: confusing documentation surrounding an extrapyramidal reaction.
    Kanarek BB; Curnow R; Palmer J; Cook SF
    J Clin Oncol; 1992 Mar; 10(3):506-7. PubMed ID: 1531497
    [No Abstract]   [Full Text] [Related]  

  • 31. Ondansetron: a new entity in emesis control.
    Graves T
    DICP; 1990 Nov; 24(11 Suppl):S51-4. PubMed ID: 2148659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and economic impact of oral ondansetron for vomiting in a pediatric emergency department.
    Hervás D; Armero C; Carrión T; Utrera JF; Hervás JA
    Pediatr Emerg Care; 2012 Nov; 28(11):1166-8. PubMed ID: 23114242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balancing efficacy with cost: antiemetic control in the pediatric stem cell transplant (SCT) population.
    Parsons SK; Hoorntje LE; Levine KJ; Mayer DK; Eichelberger WJ; Guinan EC
    Bone Marrow Transplant; 2000 Mar; 25(5):553-7. PubMed ID: 10713635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
    Schmoll HJ
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S35-9. PubMed ID: 2533897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
    Plosker GL; Milne RJ
    Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is ondansetron "too expensive"?
    Pannuti F; Tanneberger S; Lelli G; Piana E
    Lancet; 1992 Mar; 339(8793):614-5. PubMed ID: 1347112
    [No Abstract]   [Full Text] [Related]  

  • 37. 2005 Medicare payments for chemotherapy will exceed costs.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jan; 97(1):7. PubMed ID: 15632370
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
    Kwong WJ; Parasuraman TV
    Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of ondansetron vs dimenhydrinate for prevention of postoperative vomiting in children undergoing strabismus surgery.
    Piwko C; Lasry A; Alanezi K; Coyte PC; Ungar WJ
    Paediatr Anaesth; 2005 Sep; 15(9):755-61. PubMed ID: 16101706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical pharmacology of ondansetron.
    Blackwell CP; Harding SM
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S21-4; discussion S25-7. PubMed ID: 2533895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.